Tech firm readies for rollout of online med-monitoring system
CRYSTAL LAKE, Ill. An online technology and communications firm says it is ready to take a new alert and communications system for medication adherence to the next level by testing its widespread application among everyday users.
The system, called eMedonline and developed by Leap of Faith Technologies, relies on cell phone technology and barcode scanning technology to help patients remain safe and compliant with their medication therapy. The system—which can also be harnessed for clinical trials and other uses—includes a wireless device for use in a patient’s home, along with Web-based services that collect and distribute information between the patient and clinician, according to the company.
“eMedonline can be thought of as a ‘smart service’ that leverages the inherent abilities of wireless technologies like cell phones and radiofrequency identification to facilitate medication compliance and remote patient monitoring,” noted Leap of Faith in a report on the product. “It functions as a system that includes a cell phone, RFID, and Web-based services that collect and distribute information between the patient and clinician.
The system works via smartphone technology and either barcode scanning or RFID technology to track and record the medication package. The eMedonline system automatically collects and transmits specific data for individual patients—including dosing times, missed doses, and outcomes data—in real time from a single device. “Medication data read from an RFID tag is collected in real time and helps patients verify that they are taking the correct medicine at the correct time, while helping caregivers and clinicians appropriately intervene in the case of missed medications or adverse events before they become a significant health risk,” Leap of Faith stated.
“The data can be analyzed through the eMedonline clinical interface, or exported for use in other clinical monitoring systems,” noted the company. “It provides important information on the medication and health status of an individual patient, and on the patient population as a whole.”
FDA announces safety review of two immunosuppressive drugs
WASHINGTON The Food and Drug Administration issued an early communication today stating that an ongoing safety review is taking place about the immunosuppressive medications CellCept by Roche and Myfortic by Novartis.
The drugs have been linked in safety data provided by Roche to progressive multifocal leukoencephalopathy, a sometimes fatal disorder that affects the central nervous system.
Roche has recommended including this information in the CellCept label. The active ingredient in CellCept, mycophenolate mofetil, is metabolized by the body to MPA (mycophenolic acid), the active drug ingredient in Myfortic.
The FDA anticipates taking two months to complete its review of the safety data and the proposed revised labeling for CellCept and Myfortic that includes information about PML.
MyInsuranceExpert.com launches in nine states
BLOOMFIELD HILLS, Mich. A new Web site called MyInsuranceExpert.com helps individuals and families research and purchase insurance policies, according to published reports.
MyInsuranceExpert.com is available in Michigan and eight other states and hopes to expand to 40 states by the end of 2009. So far, he said the site’s biggest business comes from states like Texas and Florida, where there are fewer companies offering insurance to employees.
People go to the site to receive online quotes and ultimately purchase their insurance policy. But the site also has personal, licensed advisers who work with each client to ensure they have the most cost-effective policy possible.